---
schema_version: "secwatch.filing_event.v1"
accession: "0001714899-24-000205"
form_type: "8-K"
ticker: "DNLI"
cik: "0001714899"
company_name: "Denali Therapeutics Inc."
filed_at: "2024-10-10T23:59:59+00:00"
generated_at: "2026-05-30T16:43:52.017269+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Denali partner Sanofi discontinues K2 Phase 2 study of oditrasertib in MS after missing endpoints

## Summary
- Sanofi discontinued K2 Phase 2 study of oditrasertib (SAR443820/DNL788) in multiple sclerosis.
- Study did not meet primary and key secondary endpoints based on serum neurofilament light chain levels.
- Denali was informed by partner Sanofi; no further details on safety or next steps provided.

## SEC filing metadata
- accession: 0001714899-24-000205
- form_type: 8-K
- ticker: DNLI
- cik: 0001714899
- company_name: Denali Therapeutics Inc.
- filed_at: 2024-10-10T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1714899/000171489924000205/0001714899-24-000205-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1714899/000171489924000205/dnli-20241010.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001714899-24-000205
- JSON: https://secwatch.observer/filing/0001714899-24-000205.json
- Plain text: https://secwatch.observer/filing/0001714899-24-000205.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.